Evidence map›Paper›PMID 20508519›Full record

ReviewCurrent opinion in clinical nutrition and metabolic care2010

Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease.

Josep Bassaganya-Riera, Raquel Hontecillas

Abstract readReview
In one paragraph

Review in Current opinion in clinical nutrition and metabolic care, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. The association between dairy products and the risk of COVID-19.European journal of clinical nutrition · 2022
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. An overview of yeast probiotics as cancer biotherapeutics: possible clinical application in colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. A novel anti-inflammatory role of GPR120 in intestinal epithelial cells.American journal of physiology. Cell physiology · 2016
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Josep Bassaganya-RieraLaboratory of Nutritional Immunology and Molecular Nutrition, Virginia Bioinformatics Institute, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA. jbassaga@vt.edu
Raquel Hontecillas
Virginia Tech · US

Funding

Mechanisms of Immune Modulation by Abscisic AcidR01AT004308 · NCCIH · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI BASSAGANYA-RIERA, JOSEP · 2007 to 2010
$1.2M
NCCIH NIH HHS R01 AT004308
6 · The paper itself

Abstract

purpose of reviewInflammatory bowel disease (IBD) is a debilitating and widespread immune-mediated illness of unknown etiology. Current treatments are modestly successful and with significant side-effects. The purpose of this review is to summarize the current understanding of mechanisms of action underlying the anti-inflammatory actions of conjugated linoleic acid (CLA) and n-3 polyunsaturated fatty acids (PUFAs) in IBD. RECENT

findingsNutrition-based interventions that target peroxisome proliferator-activated receptors (PPARs) such as dietary CLA and n-3 PUFA have demonstrated anti-inflammatory efficacy in animal models of IBD. Clinical data on n-3 PUFA in IBD remains generally unimpressive, although results of a recent human study demonstrate that IBD remission can be maintained by maintaining the n-3: n-6 ratio more than 0.65 via n-3 PUFA intervention. In mice, CLA prevented inflammation-driven colorectal cancer by activating PPAR gamma and modulating regulatory T cells and macrophages. CLA is the subject of an ongoing clinical study in Crohn's disease patients. SUMMARY: Compelling evidence demonstrates that n-3 PUFA and CLA prevent or ameliorate IBD in animal models. However, this basic knowledge has not been translated into novel nutrition-based clinical interventions. For both compounds there is an urgent need for placebo-controlled, large-scale, multicenter clinical trials.

Indexed as

Dietary SupplementsAnimalsColorectal NeoplasmsFatty Acids, Omega-3HumansInflammatory Bowel DiseasesLinoleic Acids, ConjugatedMacrophagesPeroxisome Proliferator-Activated ReceptorsT-Lymphocytes, RegulatoryFatty Acids, Omega-3Linoleic Acids, ConjugatedPeroxisome Proliferator-Activated Receptors

Identifiers

PMID20508519
PMCPMC2947030
OpenAlexW2047495971

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.